A Randomized Phase II Trial of Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer: Hoosier Cancer Research Network GU15-215
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Transitional Cell, Ureter, Urethral, Renal Pelvis, Urothelial
Stage 4
Phase 2
Open to Enrollment
1st Line
Atezolizumab and Bevacizumab
PD-L1 Antibody; VEGFR Antibody
Dan Vaena, MD
Hoosier Cancer Research Network
Transitional Cell Carcinoma
- ECOG PS 0-2
- Histological or cytological evidence of urothelial (transitional cell) carcinoma of the renal pelvis, ureter, bladder or urethra
- Locally advanced/unresectable disease as determined by site attending urologic oncologist or metastatic disease
- Evaluable untreated tumor tissue for biomarker analysis.
- Willing to undergo a core needle or excisional biopsy on-treatment.
- Measurable disease
- No prior chemotherapy for locally advanced or metastatic urothelial cancer
- Perioperative chemotherapy previously administered in the neoadjuvant and/or adjuvant setting is permitted
- Ineligible for cisplatin as defined by presence of one or more of the following:
- Impaired renal function [GFR ≥ 30 but ≤ 60 cc/min].
- Grade ≥ 2 Hearing Loss (hearing loss measured by audiometry of 25 dB at two contiguous frequencies)
- Grade ≥ 2 peripheral neuropathy
- ECOG Performance Status of 2
- Solitary Kidney
- No Active or untreated central nervous system (CNS) metastases. Patients with treated asymptomatic CNS metastases are eligible, provided they meet all of the following criteria:
- Evaluable or measurable disease outside the CNS
- No metastases to midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)
- No history of intracranial or spinal cord hemorrhage
- No evidence of significant vasogenic edema
- No ongoing requirement for dexamethasone as therapy for CNS disease; anticonvulsants at a stable dose allowed
- No stereotactic radiation, whole-brain radiation within 4 weeks prior to Cycle 1 Day 1
- Patients with central nervous system (CNS) metastases treated by neurosurgical resection or brain biopsy within 3 months prior to Cycle 1 Day 1 will be excluded
- No malignancies other than urothelial cancer within 5 years prior
- No history of autoimmune disease
- Known HIV, HBV, or HCV
- No inadequately controlled hypertension (defined as persistent systolic blood pressure (SBP) > 150 and/or diastolic blood pressure (DBP) > 100 mmHg)
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBladder Cancer, Urothelial Cancer, Transitional Cell Carcinoma, Ureter, Renal Pelvis
Stage 4
Phase 3
Open to Enrollment
1st Line
Durvalumab, Tremelimumab
PD-L1 antibody, CTLA-4 antibody
Dan Vaena, MD
AstraZeneca
Transitional cell carcinoma
- Unresectable or metastatic transitional cell carcinoma or the urothelium (renal pelvis, ureters, urinary bladder, or urethra)
- Both transitional cell and mixed transitional/non-transitional cell histologies are permitted
- No prior 1st line therapy for metastatic disease
- Prior adjuvant therapy allowed if it has been >12 months since last therapy
- Prior local intervesical chemo or immune therapy is allowed if at least 28 days before study treatment
- Either cisplatin-eligible or cisplatin-ineligible but carboplatin eligible patients are allowed
- Measurable disease
- ECOG PS 0-1
- No prior immunotherapy with exception of BCG or antitumor vaccines
- No autoimmune disease requiring immunosuppression
- No untreated CNS disease
- No contraindications to platinum-based doublet chemotherapy
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)
Stage 4
Phase 2
Open to Enrollment
Following all effecive therapy (late line)
Pemigatinib
FGFR inhibitor
Dan Vaena, MD
Incyte Corporation
FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation
- Metastatic or surgically unresectable solid tumor
- Measurable disease
- Documentation of an FGFR1-3 gene mutation or translocation
- At least 1 prior line of therapy with progression
- No other therapy available likely to provide clinical benefit
- ECOG PS 0-2
- No other FGFR inhibitors within last 6 months
- No clinically significant corneal or retinal disorder
- No untreated CNS disease (except primary brain cancer)
- No additional malignancy at current time requiring active treatment
- No history of calcium or phosphate disorder or systemic mineral imbalance
- No clinically significant cardiac disease
- No active HBV/HCV
- No known HIV
My Pathway: An open-label Phase IIA study evaluating trastuzumab/pertuzumab, erlotinib, vemurafenib, vismodegib/cobimetinib, alectinib, and atezolizumab in patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, Endometrial, Uterine, Ovarian, Cervical, Colon, colorectal, biliary, gastric, esophageal, sarcoma, pancreatic, bladder, prostate
Stage 4
Phase 2
Open to Enrollment
2ndline or later
Atezolizumab
PD-L1 inhibitor
Ari VanderWalde, MD
Genentech
Solid tumor
- PD-L1 copy number gain/amplification (likely available on Foundation only)
- Patients with MSI-high
- Using either Foundation 1 or other NGS defined by a shift in the size of 30% or more loci
- Patients with dMMR
- Defined as loss of at least one of four markers (MLH1, MSH2, PMS2, MSH6)
- Patients with total mutational burden (TMB) high
- 10 mut/Mb per any CLIA certified test
- Patients with alterations in DNA proofreading/repair genes
- POLE mutations
- POLD1 mutations
- Mutations in genomic instability genes eg. MSH2, MLH1, MSH6
- If testing was not performed by Foundation Medicine, new pretreatment tissue sample is required. Tissue may be submitted within 4 weeks after enrollment
- No metastatic non-small cell lung cancer (no NSCLC)
- No metastatic urothelial carcinoma (no bladder cancer)
- No MSI-high colorectal cancer
- No history of autoimmune disease or immune deficiency
- No HIV/HBV/HCV
- No other malignancy within 5 years
- No need for immunosuppressive medications (including steroids)
An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma
Stage 4
Phase 2
Open to Enrollment
Any (provided no curative therapy available)
Neratinib
pan-HER TKI
Lee Schwartzberg, MD
Puma Biotechnologies
HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer
- Histologically confirmed cancer for which no curative therapy exists
- Documented HER2 (ERBB2) or HER4 (ERBB4) mutation in any malignancy or EGFR ex 18 mutations in lung cancer.
- Currently CLOSED cohorts include: HER2mt lung, colorectal, and biliary
- At least one measurable or evaluable lesion
- LVEF >/=50%
- ECOG PS 0-2
- No prior treatment with ERBB2 (HER2) directed TKIs (eg lapatinib, afatinib, neratinib)
- No symptomatic or unstable brain mets (stable are allowed)
- No cumulative prior anthracycline dose >450mg/m2 doxorubicin or equivalent
- No uncontrolled cardiac disease
- No chronic diarrheal disorder
A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Stage 4
Phase 1
Open to Enrollment
Late line
COM-701, PD(L)-1 antibody
PVRIG monoclonal antibody, PD(L)-1 antibody
Dan Vaena, MD
Compugen
- Histologically or cytologically confirmed, metastatic solid malignancy
- Has exhausted all available standard therapy or not a candidate for standard therapy
- ECOG PS 0-1
- Prior PD-1/PD-L1 allowed
- No other malignancy within 2 years prior
- No active autoimmune disease requiring systemic therapy within last 2 years
- No chronic steroids or immunosuppressants.